Alan Closes a €173 Million Funding Round Led by Belfius

Alan gains momentum. The health insurer has closed a €173 million Series F funding round, in an operation led by Belfius together with other already committed investors: Otpp through Teachers’ Venture Growth, Temasek, Coatue, Lakestar, among others. With this, its valuation has risen to €4 billion, consolidating its position in the healthtech sector.

Following this new round, Alan maintains full control of his treasury and reaffirms his objective of achieving profitability of the group by 2026, ten years after its founding in France. This investment will allow it to accelerate its growth, continue to strengthen its technological advantage and expand its international development. It will also serve to boost the development of new health programmes and services focused on self-care and prevention.

Commenting on this announcement, Jean-Charles Samuelian, CEO of Alan, said: “This privileged partnership with Belfius has been very inspiring and opens a new era for Alan. Belfius’ investment will allow us to accelerate our development and expand our capacity to offer cutting-edge, tailored and accessible healthcare products and services to a very wide audience.”

Alan’s round seen as a new boost for the Spanish market

The news of this new round of financing reaches Spain at the same time as Yoann Artus, who has recently joined Alan as CEO. With his incorporation, Alan begins a new stage in its growth where Yoann Artus’ vision on innovation will be one of the key points for the company. Artus has a great track record of more than fifteen years in Spain in companies such as Privalia, Veepee, Treatwell or PayFit.

“As a healthcare partner, at Alan we work to develop a holistic healthcare experience that allows people to take care of themselves in all aspects of their lives. More and more companies are demanding innovative and accessible resources to take care of their health and physical and mental wellbeing,” explained Yoann Artus.

For his part, Jean-Charles Samuelian said that “with this new round of investment we will continue to invest in the Spanish market and its growth.” Alan España’s plans include expanding the team to cover key positions such as sales manager, to face the new challenges that are to come and respond to the growing demand for innovative health products in the Spanish market, where the company entered in 2020.

In addition, during 2025, Alan plans to expand its health services offering. Its flexible remuneration product, called Healthy Benefits, will be joined by new programs that will allow its users to directly treat their back pain without having to go to a physiotherapist, manage stress, resolve their doubts about different symptoms or motivate themselves to maintain an active life.

The aim of these services is to break health paradigms, as well as to combat and prevent some of the most common problems among Spaniards such as a sedentary lifestyle, stress (which affects 60% of workers), musculoskeletal problems (main cause of sick leave) or cardiovascular problems, the main cause of death in Spain.

__

(Featured image by Markus Winkler via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us